Apellis Pharmaceuticals (APLS) News Today $17.44 -0.34 (-1.91%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$17.55 +0.11 (+0.61%) As of 05/23/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Citigroup Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00May 25 at 2:50 AM | americanbankingnews.comRoyal Bank of Canada Acquires 1,376,832 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Royal Bank of Canada lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 969.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,518,827 sharesMay 24 at 4:24 AM | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-one analysts that are currently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating, eleven hMay 22 at 2:04 AM | marketbeat.comToronto Dominion Bank Purchases 971,431 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Toronto Dominion Bank raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3,791.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 997,053 shares of the company's stock after acquiring an additional 971,4May 21, 2025 | marketbeat.comGotham Asset Management LLC Purchases New Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Gotham Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 24,299 shares of the company's stock, valued at approxiMay 21, 2025 | marketbeat.comApellis Pharmaceuticals: Have Some PatienceMay 20, 2025 | seekingalpha.comRafferty Asset Management LLC Has $7.71 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Rafferty Asset Management LLC boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 18.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,474 shares of the coMay 20, 2025 | marketbeat.com793,187 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Purchased by Suvretta Capital Management LLCSuvretta Capital Management LLC acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 793,187 shares of tMay 19, 2025 | marketbeat.comPoint72 Asset Management L.P. Invests $40.46 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Point72 Asset Management L.P. purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,267,958 shares of the cMay 18, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading 5.9% Higher - Here's What HappenedMay 18, 2025 | americanbankingnews.comPoint72 Europe London LLP Buys Shares of 192,694 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Point72 Europe London LLP purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 192,694 shares of the company's stock, valued at approximately $6,149,000. Point72 EuropeMay 17, 2025 | marketbeat.comPolar Capital Holdings Plc Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Polar Capital Holdings Plc grew its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 45.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,577,175 shares of the company's sMay 17, 2025 | marketbeat.comNorthern Trust Corp Has $17.46 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Northern Trust Corp lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 547,276 shares of the company's stock afteMay 17, 2025 | marketbeat.comBank of America Corp DE Has $53.62 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Bank of America Corp DE increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 72.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,680,213 shares of the company's stock aMay 16, 2025 | marketbeat.comAmeriprise Financial Inc. Boosts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Ameriprise Financial Inc. boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 882,801 shares of the company's stockMay 16, 2025 | marketbeat.comDeutsche Bank AG Has $56.75 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Deutsche Bank AG boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,778,377 shares of the company's stock after purchasing an addiMay 15, 2025 | marketbeat.comBaird Financial Group Inc. Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Baird Financial Group Inc. grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 101.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,665 shares of the compMay 15, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Sets New 12-Month Low Following Analyst DowngradeMay 15, 2025 | americanbankingnews.comIntegral Health Asset Management LLC Acquires New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Integral Health Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 420,000 shares of theMay 14, 2025 | marketbeat.comHudson Bay Capital Management LP Buys 85,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Hudson Bay Capital Management LP increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 32.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 345,000 shares of theMay 14, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of APLS FY2025 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earningMay 13, 2025 | marketbeat.comHC Wainwright Has Negative Estimate for APLS Q2 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Apellis Pharmaceuticals in a research note issued on Thursday, May 8th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.49) per shareMay 13, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for Apellis PharmaceuticalsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush reduced their Q2 2025 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 7th. Wedbush analyst L. Chico now expects that the compaMay 13, 2025 | marketbeat.comWilliam Blair Issues Pessimistic Forecast for APLS EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued on Wednesday, May 7th. William Blair analyst L. Hanbury-Brown now forecasts that theMay 13, 2025 | marketbeat.comWells Fargo & Company MN Sells 133,752 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Wells Fargo & Company MN lessened its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 96.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,616 shares of the company's stock after selling 133,752 shareMay 12, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Outperform" Rating by Raymond JamesRaymond James cut Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and set a $52.00 target price for the company. in a report on Friday.May 11, 2025 | marketbeat.comBank of America Downgrades Apellis Pharmaceuticals (NASDAQ:APLS) to NeutralBank of America lowered shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $23.00 price target for the company. in a report on Friday.May 11, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $6.12 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Cubist Systematic Strategies LLC acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 191,687 shares of the company's stock, valMay 11, 2025 | marketbeat.comBNP Paribas Financial Markets Buys 691,123 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)BNP Paribas Financial Markets grew its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 432.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 850,823 shares of the company'sMay 11, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $47.00 Price Target at Robert W. BairdRobert W. Baird decreased their target price on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a research report on Thursday.May 10, 2025 | marketbeat.comB of A Securities Downgrades Apellis Pharmaceuticals (APLS)May 10, 2025 | msn.comApellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’May 9, 2025 | finance.yahoo.comIs Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back?May 9, 2025 | msn.comApellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year Low After Earnings MissApellis Pharmaceuticals (NASDAQ:APLS) Hits New 1-Year Low on Disappointing EarningsMay 9, 2025 | marketbeat.comDeep Track Capital LP Reduces Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Deep Track Capital LP lowered its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,274,921 shares of the company's stMay 9, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Balyasny Asset Management L.P.Balyasny Asset Management L.P. increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1,388.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 744,194 shares ofMay 9, 2025 | marketbeat.comWhy Apellis Pharmaceuticals Wilted on WednesdayMay 8, 2025 | msn.comBraidwell LP Sells 1,026,317 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Braidwell LP decreased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 32.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,098,866 shares of the company's stock after sellingMay 8, 2025 | marketbeat.comApellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ...May 8, 2025 | finance.yahoo.comApellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | finanznachrichten.deApellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comApellis Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 7, 2025 | seekingalpha.comApellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issuesMay 7, 2025 | au.investing.comApellis Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comAlgert Global LLC Acquires 199,874 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Algert Global LLC boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 242.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 282,285 shares of the company's stoMay 7, 2025 | marketbeat.comApellis Pharmaceuticals Q1 2025 Earnings PreviewMay 6, 2025 | msn.comApellis Pharmaceuticals to Present at Upcoming Investor ConferencesMay 6, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Reduces Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Price T Rowe Associates Inc. MD lowered its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 358,578 shares of the compMay 5, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Raymond James Financial Inc. bought a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 49,015 shares of the company's stock, valued at approximately $1,564,000. A numMay 5, 2025 | marketbeat.comBoxer Capital Management LLC Purchases New Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Boxer Capital Management LLC acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,426,000 sharesMay 4, 2025 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.940.77▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼99▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News RVMD News ELAN News BPMC News BBIO News VRNA News TLX News TGTX News GRFS News LNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APLS Stock Free APLS Stock Alerts